MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

69.93 1.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

68.91

Максимум

71.8

Ключови измерители

By Trading Economics

Приходи

270M

124M

Продажби

320M

452M

Марж на печалбата

27.331

Служители

1,069

EBITDA

294M

150M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+10.31% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.4B

11B

Предишно отваряне

68.48

Предишно затваряне

69.93

Настроения в новините

By Acuity

50%

50%

183 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2025 г., 16:58 ч. UTC

Печалби

BMW Trims 2025 View, Citing Weaker Performance in China

7.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7.10.2025 г., 23:19 ч. UTC

Пазарно говорене

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7.10.2025 г., 22:40 ч. UTC

Пазарно говорене

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 20:44 ч. UTC

Горещи акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7.10.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7.10.2025 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7.10.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7.10.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7.10.2025 г., 15:25 ч. UTC

Пазарно говорене

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7.10.2025 г., 15:15 ч. UTC

Пазарно говорене

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7.10.2025 г., 14:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

10.31% нагоре

12-месечна прогноза

Среден 76.05 USD  10.31%

Висок 96 USD

Нисък 46 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

17

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

183 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat